Blog

Oncoshot was recognised as winner for the Health Products & Services category, for its commitment to elevate cancer treatment through technology.

The global study explores the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE with durvalumab plus bevacizumab therapy.

The regional media outlet highlighted Oncoshot's contributions in fostering a more collaborative, data-driven cancer clinical trial landscape.

The Phase I and II single-arm pilot study with multiple cohorts of patient populations harnesses AI for personalised guidance of an individual’s dose modulations based only on his/her data. It aims to re-look at the way oncology clinical trials are designed.

Tech-powered solutions such as data-driven pre-screening tools can enable more accurate feasibility studies, thus improving cancer clinical trial enrolment rates.

He leads a Phase III, randomised, open-label study of Atezolizumab plus Bevacizumab versus active surveillance as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after surgical resection or ablation.

The phase III, randomised, double-blind, placebo-controlled study evaluates the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in patients who meet the specific trial criteria.

Oncoshot won in the Healthtech category of the Startup Awards, which honour regional startups that embody the spirit of innovation and entrepreneurship.

The free service is designed to help busy oncologists identify promising cancer clinical trials for their patients in an efficient manner.

With cancer continuing to be a leading cause of mortality worldwide, cutting-edge cancer clinical trials can help you expand your treatment options.

In light of Breast Cancer Awareness month in October, we highlight potentially live-saving detection methods and new therapies - including those you may access through clinical trials.